Mahzi Therapeutics Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Mahzi Therapeutics Inc. - overview
Established
2020
Location
San Mateo, CA-California, US
Primary Industry
Biotechnology
About
Founded in 2020 and based in California, US, Mahzi Therapeutics Inc. is a healthcare and biotechnology research company that focuses on treating rare genetic neurodevelopmental disorders. In October 2022, Mahzi Therapeutics Inc. raised USD 4 million in Series A funding from HBM Partners.
As of 2023, the company is led by its CEO, Yael Weiss. The company has expertise in identifying and developing tailored therapeutic approaches for each distinct neurodevelopmental disorder. The firm’s pipeline includes disease identification and understanding, where the initial phase involves comprehensive research to identify, comprehend, and define the specific nuances of each targeted disorder, such as WOREE/SCAR12 (WWOX Deficiency), Pitt Hopkins (TCF4 Deficiency), and CHD2 Deficiency. The firm then undergoes pre-clinical development and conducts pre-clinical studies, employing scientific methodologies to assess the feasibility and efficacy of potential therapeutic interventions.
Mahzi then focuses on meeting regulatory requirements and ensuring the safety and efficacy of its prospective treatments before advancing to human trials. Finally, the company initiates human trials to evaluate the safety and efficacy of the developed therapies.
Current Investors
HBM Partners
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals
Website
www.mahzi.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Mahzi Therapeutics Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A | Completed | Mahzi Therapeutics Inc. | - | ||||||||
| Series A | Completed | Mahzi Therapeutics Inc. | - |
Displaying 1 - 2 of 2
Mahzi Therapeutics Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.